
Integra LifeSciences Holdings Corporation IART
$ 15.88
2.25%
Integra LifeSciences Holdings Corporation General and Administrative Expenses | IART
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Integra LifeSciences Holdings Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 700 M | 717 M | 657 M | 616 M | 637 M | 595 M | 688 M | 691 M | 624 M | 456 M | 416 M | 446 M | 394 M | 373 M | 358 M | 305 M | 281 M | 281 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 717 M | 281 M | 513 M |
Quarterly General and Administrative Expenses Integra LifeSciences Holdings Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 172 M | 178 M | 169 M | 180 M | 181 M | 177 M | 195 M | 166 M | 162 M | 165 M | 167 M | - | 144 M | 161 M | 160 M | - | 156 M | 163 M | 157 M | - | 150 M | 116 M | 166 M | - | 173 M | 165 M | 175 M | - | 173 M | 177 M | 164 M | - | 146 M | 145 M | 142 M | - | 112 M | 119 M | 112 M | - | 113 M | 99.3 M | 93.3 M | - | 93.8 M | 115 M | 108 M | - | 99.8 M | 103 M | 103 M | - | 93.1 M | 96.1 M | 87.4 M | - | 87.5 M | 95.7 M | 80.1 M | 75.7 M | 74.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 74.2 M | 137 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
946 M | $ 64.0 | 7.26 % | $ 9.72 B | ||
|
Boston Scientific Corporation
BSX
|
6.89 B | $ 44.68 | 0.06 % | $ 66.1 B | ||
|
Cognyte Software Ltd.
CGNT
|
47.1 M | $ 8.7 | 0.06 % | $ 634 M | ||
|
ClearPoint Neuro
CLPT
|
16.5 M | $ 14.61 | 13.03 % | $ 414 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 45.18 | 3.31 % | $ 1.4 B | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 4.3 | 1.63 % | $ 268 M | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 16.08 | 0.75 % | $ 576 M | ||
|
Medigus Ltd.
MDGS
|
9.96 M | - | 10.28 % | $ 55.5 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
Electromed
ELMD
|
42.7 M | $ 27.86 | 1.05 % | $ 230 M | ||
|
Establishment Labs Holdings
ESTA
|
165 M | $ 65.58 | 3.69 % | $ 1.94 B | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 85.73 | 0.32 % | $ 50.1 B | ||
|
Nemaura Medical
NMRD
|
5.6 M | - | -17.8 % | $ 2.74 M | ||
|
AdaptHealth Corp.
AHCO
|
382 M | $ 5.57 | 0.43 % | $ 753 M | ||
|
Helius Medical Technologies
HSDT
|
23.1 M | $ 2.9 | 0.69 % | $ 63.9 M | ||
|
Inogen
INGN
|
67.4 M | $ 5.23 | 2.75 % | $ 139 M | ||
|
InMode Ltd.
INMD
|
11.7 M | $ 14.19 | 0.21 % | $ 917 M | ||
|
Inspire Medical Systems
INSP
|
625 M | $ 68.81 | 0.59 % | $ 2.02 B | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
7.73 M | $ 0.63 | 2.51 % | $ 10.7 M | ||
|
IRadimed Corporation
IRMD
|
17.8 M | $ 85.2 | 0.08 % | $ 1.08 B | ||
|
AxoGen
AXGN
|
44.6 M | $ 43.32 | 0.48 % | $ 1.99 B | ||
|
Align Technology
ALGN
|
1.76 B | $ 145.63 | 4.36 % | $ 10.6 B | ||
|
LENSAR
LNSR
|
45.2 M | $ 7.08 | 0.28 % | $ 84.7 M | ||
|
Sientra
SIEN
|
41.5 M | - | -16.59 % | $ 10.3 M | ||
|
Silk Road Medical, Inc
SILK
|
145 M | - | - | $ 1.07 B | ||
|
Medtronic PLC
MDT
|
11.8 B | $ 88.51 | 0.32 % | $ 113 B | ||
|
MiMedx Group
MDXG
|
56.5 M | $ 4.71 | 0.1 % | $ 696 M | ||
|
Surgalign Holdings
SRGA
|
95.9 M | - | -32.98 % | $ 1.68 M | ||
|
ShockWave Medical
SWAV
|
95.3 M | - | - | $ 12.3 B | ||
|
Myomo
MYO
|
14 M | $ 1.67 | 1.83 % | $ 69.9 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
21.6 M | $ 0.66 | 0.45 % | $ 42.8 M | ||
|
InspireMD
NSPR
|
20.7 M | $ 0.7 | 0.37 % | $ 45 M | ||
|
Orthofix Medical
OFIX
|
554 M | $ 9.16 | 0.11 % | $ 363 M | ||
|
Outset Medical
OM
|
37.9 M | $ 3.13 | 1.29 % | $ 47.6 K | ||
|
Insulet Corporation
PODD
|
1.16 B | $ 135.78 | 0.01 % | $ 9.55 B | ||
|
Profound Medical Corp.
PROF
|
32.1 M | $ 5.6 | 1.66 % | $ 169 M | ||
|
Titan Medical
TMDI
|
12.4 M | - | -26.32 % | $ 19.6 M | ||
|
Quanterix Corporation
QTRX
|
138 M | $ 3.18 | 0.63 % | $ 136 M | ||
|
Natus Medical Incorporated
NTUS
|
52.8 M | - | 1.94 % | $ 1.05 B | ||
|
AVITA Medical
RCEL
|
27.4 M | $ 11.58 | 5.75 % | $ 323 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
Apyx Medical Corporation
APYX
|
15.8 M | $ 2.83 | 1.37 % | $ 116 M | ||
|
Sintx Technologies
SINT
|
6.2 M | $ 1.87 | 5.06 % | $ 5.19 M | ||
|
Accuray Incorporated
ARAY
|
45.4 M | $ 0.22 | 0.4 % | $ 27 M | ||
|
Smith & Nephew plc
SNN
|
3.1 B | $ 26.68 | 0.02 % | $ 23.1 B | ||
|
Inari Medical
NARI
|
361 M | - | - | $ 4.23 B |